Latest Headlines

Latest Headlines

Malaria vaccine proves promising in Mali trial

An experimental malaria vaccine originally developed by GlaxoSmithKline and the U.S. Army has produced dramatic results in an early-stage trial in Mali. Researchers recruited 100 children who are

Glaxo promises "sustainable" malaria vax price

Glaxo's Andrew Witty says he'll price the company's new malaria vaccine just over cost. And any profits, he pledges, will be plowed back into research. Analysts say that more than $500 million has

Study: HPV shot will slash cervical cancer rates

The number of women under the age of 30 diagnosed with cervical cancer will fall nearly two thirds by 2025 because they have received the HPV vaccine, according to a study published this week in the

Glaxo chief promises another giveaway

Last year, GlaxoSmithKline chief Andrew Witty made a series of moves that made some pharma watchers ask, "What the heck?" Cutting prices in the developing world, contributing patents to a pool to

Did Sanofi's diversity boost profits 20%?

What's the best pharma business? The vaccines business. At least that's the opinion of Sanofi-Aventis CEO Chris Viehbacher. He told the J.P. Morgan Healthcare conference that this "best business" is

Merck tries again for Gardasil expansion

Merck hasn't given up on broader use of its HPV vaccine in women. The company has delivered a new batch of info to the FDA in support of Gardasil use in women aged 27 to 45. The vaccine--which wards

Insects could help meet future H1N1 vax demand

Austrian scientists are touting research involving insect cell-based technology to create recombinant influenza virus-like particles (VLPs)--a discovery that could lead to faster production times for

Most U.S. vax advisers had conflicts of interest

Most of the experts who served on federal review panels for new vaccines in 2007 had conflicts of interest that were either never discovered or never resolved, according to a new report from the

Low vax demand could threaten H1N1 profits

Some European customers are negotiating to return millions of unused doses of H1N1 vaccine to four suppliers, threatening the companies' huge revenue boost from the global pandemic. Apparently,

Germany, Spain want to return unused H1N1 vaccine

With even the most vulnerable segments of their populations shrugging off the threat of swine flu, Germany and Spain want to hand back unused stockpiles of the H1N1 vaccine. And if other countries